Allurion Technologies Inc.

ALUR ·Healthcare, Medical Devices, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024 Jun 2024
Operating Activities
Net Income $-6.1M $-6.0M $-11.9M $-9.3M $-1.5M $-9.6M $8.7M $-8.3M
Depreciation & Amortization $171.0K $167.0K $267.0K $346.0K $203.0K $218.0K $215.0K $197.0K
Depreciation $200.0K $200.0K $300.0K $300.0K $200.0K $200.0K $200.0K $200.0K
Amortization — — — — — — — —
Stock-Based Compensation $638.0K $702.0K $531.0K $1.0M $897.0K $839.0K $860.0K $805.0K
Net Cash from Operating Activities $-3.2M $-5.3M $-6.5M $-7.6M $-9.5M $-13.3M $-11.5M $-8.9M
Investing Activities
Capital Expenditures — — — — — $0 $72.0K $435.0K
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities — — — — — $0 $-72.0K $-435.0K
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $2.9M $4.6M $-55.0K $-71.0K $14.5M $-53.0K $20.9M $-1.1M
Net Change in Cash $-355.0K $-723.0K $-6.6M $-7.7M $5.0M $-13.3M $9.4M $-10.4M
Free Cash Flow — — — — — $-13.3M $-11.5M $-9.4M
← Newer Page 1 of 2 Older →